Skip Navigation


Carcinogenesis Advance Access originally published online on May 23, 2007
Carcinogenesis 2007 28(8):1759-1764; doi:10.1093/carcin/bgm121
This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary Data
Right arrow All Versions of this Article:
28/8/1759    most recent
bgm121v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Morton, L. M.
Right arrow Articles by Zahm, S. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morton, L. M.
Right arrow Articles by Zahm, S. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Hair dye use, genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma

Lindsay M. Morton*, Leslie Bernstein1, Sophia S. Wang, David W. Hein2, Nathaniel Rothman, Joanne S. Colt, Scott Davis3, James R. Cerhan4, Richard K. Severson5, Robert Welch6, Patricia Hartge and Shelia Hoar Zahm

Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Rockville, MD 20852, USA
1 Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90089, USA
2 Department of Pharmacology and Toxicology, James Graham Brown Cancer Center, University of Louisville, School of Medicine, Louisville, KY 40292, USA
3 Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA
4 Mayo Clinic, College of Medicine, Rochester, MN 55905, USA
5 Department of Family Medicine, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
6 Core Genotyping Facility, Advanced Technology Center, National Cancer Institute, NIH, DHHS, Gaithersburg, MD 20877, USA

* To whom correspondence should be addressed. Tel: +301 435 3972; Fax: +301 402 0916; Email: mortonli{at}mail.nih.gov.


   Abstract
Top
 Abstract
Introduction
 Materials and methods
 Results
 Discussion
 Funding
 Supplementary material
 References
 
Background: Several previous studies have found non-Hodgkin lymphoma (NHL) risk to be associated with hair dye use, particularly use of permanent, dark colors and use before 1980, when hair dye formulations changed.

Methods: We examined NHL risk in relation to reported hair dye use among 1321 cases and 1057 controls from a US population-based multi-center study. DNA was extracted from blood or buccal cells to identify genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), which encode enzymes that metabolize aromatic amine compounds found in hair dyes.

Results: Among women, 509 cases and 413 controls reported hair dye use [odds ratio (OR) = 1.2; 95% confidence interval (95% CI) = 0.9, 1.6]. Risk estimates were higher for use before 1980 than for use in 1980 or later, particularly for use of permanent, intense tone (black, dark brown, dark blonde) products (<1980—OR = 1.6; 95% CI 0.9, 2.7; ≥1980—OR = 0.6; 95% CI 0.4, 1.1). Risk estimates were increased for women who used permanent, intense tone products before 1980 if they had the rapid/intermediate NAT2 phenotype (OR = 3.3; 95% CI 1.3, 8.6) or the NAT1*10 allele (OR = 2.5; 95% CI 0.9, 7.6), but not if they were slow NAT2 acetylators (OR = 1.5; 95% CI 0.6, 3.6) or had no copies of the NAT1*10 allele (OR = 1.5; 95% CI 0.7, 3.3). NHL risk was not increased among women who began hair dye use after 1980 or among men.

Conclusion: Our results support previous research demonstrating elevated NHL risk among women who used dark color or intense tone permanent hair dyes before 1980. We present the first evidence suggesting that this risk may differ by genetic variation in NAT1 and NAT2.

Abbreviations: 95% CI, 95% confidence interval; DLBCL, diffuse large B-cell lymphoma; NHL, non-Hodgkin lymphoma; NAT, N-acetyltransferase; OR, odds ratio; SEER, Surveillance Epidemiology and End Results; SNP, single-nucleotide polymorphism


   Introduction
Top
 Abstract
 Introduction
Materials and methods
 Results
 Discussion
 Funding
 Supplementary material
 References
 
Non-Hodgkin lymphoma (NHL) has been associated with use of hair coloring products, particularly long-term use of dark permanent dyes, in several previous epidemiologic studies (1–9). In 1988, Cantor et al. (1) reported a 2-fold increased risk of NHL among men who used hair coloring products. In 1992, Zahm et al. (2) reported odds ratios (ORs) of 2.0, 4.1 and 3.0 for NHL among women who used brown/brunette, black and red dye, respectively, compared with women who never used hair coloring products. Long-term use of black hair dyes has also been associated with 2- to 4-fold increased NHL mortality (3,4). A case–control study by Zhang et al. (5) observed a 2-fold increased risk of NHL among women who used dark-color permanent dyes for >25 years and began use prior to 1980, the approximate time when manufacturers removed from hair dye formulations some compounds (e.g. aromatic amine dyes) that had been found to be mutagenic and carcinogenic in animal studies (10–12). Similar findings of increased NHL risk associated with hair dye use prior to 1980 were recently reported by de Sanjose et al. (8) in Europe.

Not all studies support a role for hair dyes in the etiology of NHL (7,9). The Nurses' Health Study cohort has not shown any increased risk for NHL among hair dye users (13), nor have several case–control studies (14–16). Additionally, no study has shown consistent and strong patterns of increasing risk with increasing frequency, duration or early age at first use. In 1993, the International Agency for Research on Cancer classified the exposures of hairdressers and barbers and various compounds in hair dyes as probably or possibly carcinogenic (Groups 2A and 2B, respectively), but concluded that there was not sufficient evidence to evaluate personal use of hair dye (Group 3) (17).

It is plausible that the role of hair dyes in lymphomagenesis is modified by common genetic variation in the enzymes N-acetyltransferase 1 (NAT1) and 2 (NAT2), which are responsible for metabolizing aromatic amines such as those found in hair dyes. NAT1 and NAT2 detoxify and activate these compounds via N-acetylation and O-acetylation following N-hydroxylation, which can lead to the formation of carcinogenic intermediates. Both genotypic and phenotypic variation in NAT1 and NAT2 lead to variation in acetylation capacity, and therefore variation in the formation of carcinogenic intermediates (18). Thus, it is worthwhile to investigate the potential effects of hair dye use taking into account common genetic variation in these enzymes.

The possible carcinogenicity of hair coloring products poses an important public health issue given the high prevalence of use. The percentage of women reporting ever use of hair dyes increased dramatically from <10 to >50% with the introduction of one-step home-use kits around 1950. Over the last 30 years, the percentage of women currently using hair dyes in the US has remained constant at ~40% (19,20), and cumulative lifetime use approaches 75% among women, based on prevalence of exposure among controls in epidemiologic case–control studies (21). Hair dye use in men is somewhat less common than in women; based on a market survey conducted in 2003, 25% of men in the US reported current hair dye use (20). The high prevalence of use and the previous epidemiologic findings led us to evaluate the association between hair coloring products and NHL in a large population-based case–control study conducted in four areas of the US.


   Materials and methods
Top
 Abstract
 Introduction
 Materials and methods
Results
 Discussion
 Funding
 Supplementary material
 References
 
Study population
Study methods have been described in detail elsewhere (22–24). Briefly, cases with a histologically confirmed, first primary diagnosis of NHL (International Classification of Diseases for Oncology, Second Edition, codes 9590-91, 9595, 9670-73, 9675-76, 9680-88, 9690-91, 9695-98, 9700, 9702-03, 9705-11, 9713-15, 9823, 9827) (25), aged 20–74 years, diagnosed between July 1998 and June 2000, were identified among residents of four Surveillance Epidemiology and End Results (SEER) registries (Iowa, Los Angeles County, metropolitan Detroit and metropolitan Seattle). Known HIV-positive cases were excluded.

Controls were selected from residents of the same four SEER areas, frequency matching to the cases by age (within 5-year age groups), sex, race and SEER area. For cases under age 65, controls were selected by one-step list-assisted random digit dialing (26), with 78.5% of contacts providing household rosters. For cases aged 65 and older, controls were selected from the Center for Medicare and Medicaid Services files of residents eligible for Medicare. Controls with a history of NHL or known HIV infection were excluded.

Of 2248 presumed eligible cases, 320 (14%) died prior to interview, 127 (6%) could not be located, 16 (1%) had moved out of the area and 57 (3%) had physician refusals. Of the remaining 1728 cases, 274 (16%) declined to be interviewed and 133 (8%) never responded or were not interviewed due to illness, impairment or other reasons. A total of 1321 eligible cases were interviewed, yielding a participation rate of 76% of the cases we attempted to contact and an overall case response rate of 59%.

Of the 2409 controls identified, 28 (1%) died before contact, 311 (13%) could not be located and 24 (1%) had moved out of the geographic area. Of the remaining 2046 controls, 839 (41%) declined to be interviewed and 150 (6%) did not participate due to illness, impairment or other reasons. A total of 1057 controls were interviewed, yielding a participation rate of 52% and an overall control response rate of 44%.

In-person interviews were conducted by trained personnel, who administered a computer-assisted personal interview, blinded to case–control status. All study participants were asked to provide a venous blood or mouthwash buccal cell sample. We obtained blood samples from 773 cases and 668 controls and buccal cell samples from 399 cases and 314 controls; 149 (11%) cases and 75 (7%) controls provided neither.

The study was approved by human subjects review boards at all institutions. Written informed consent was obtained from all subjects.

Exposure assessment
In-person interviews included questions on ages of first and last use of each episode of use of temporary (products that wash out in one shampoo), semi-permanent (products that rinse out after a few shampoos), permanent (products that last until the hair grows out) and gradual (e.g. Grecian Formula®) hair coloring products. Also ascertained were color (e.g. black, brown, blonde, red), tone (e.g. light, dark), brand name, frequency of use and whether two components (e.g. color and developer) had to be mixed together. Intense tone products (i.e. black, dark brown, dark blonde) have higher concentrations of paraphenylenediamine and other dye intermediates than light or intermediate tone products (J.Skare, 2004, personal communication). Some processes, such as bleaching without adding color, were included in the screening list to elicit complete histories, but were not considered to involve hair dye exposure. Exposure histories were truncated 1 year prior to the date of diagnosis for cases and date of selection for the controls. The interview included other known and suspected risk factors for NHL, such as family history of cancer, pesticide exposure and medical history.

The methods for evaluating NAT1 and NAT2 genotypes and NAT2 acetylation phenotype in our study population have been described previously by Morton et al. (24). Briefly, DNA was extracted from blood clots or buffy coats from 10 ml blood for 773 cases and 668 controls at SeraCare BioServices (Gaithersburg, MD) using Puregene Autopure DNA extraction kits (Gentra Systems, Minneapolis, MN). DNA was extracted from buccal cells for an additional 399 cases and 314 controls by phenol chloroform extraction methods (27). Genotyping was carried out at the NCI Core Genotyping Facility (Advanced Technology Center, Gaithersburg, MD) using validated assays on the Taqman (Applied Biosystems, Foster City, CA) or MGB Eclipse (Epoch Biosciences, Bothell, WA) platforms to identify 10 single-nucleotide polymorphisms (SNPs) in NAT1 and NAT2. Sequence data and assay conditions are provided at http://snp500cancer.nci.nih.gov (28). The genotype frequencies among white, non-Hispanic controls were in Hardy–Weinberg equilibrium for all 10 SNPs (Pearson chi-square statistic >0.05). The SNP data were used to assign the most likely NAT1 and NAT2 alleles previously identified in human populations (29). For analyses of NAT1, NAT1*10 was designated as the at-risk allele based on previous research (30). For analyses of NAT2, we designated NAT2*4/*4 as the referent genotype, as has been done previously, because it corresponds to an absence of the nucleotide substitutions that define the other NAT2 genotypes (30). NAT2 acetylation phenotype was assigned at the University of Louisville (by D.W.H.) based on in vivo and in vitro data on allelic variation in catalytic activity (18). For analysis of NAT2 phenotypes, individuals homozygous for NAT2 rapid- and slow-acetylator alleles were designated as rapid- and slow-acetylators, respectively; individuals possessing one rapid- and one slow-acetylator allele (heterozygotes) were designated as intermediate acetylators (31).

Statistical analysis
Statistical analyses were performed using the SAS system, version 9.1 (SAS Institute, Cary, NC). Relative risk of NHL, or NHL subtype, was estimated using OR and 95% confidence intervals (95% CIs) derived from dichotomous and polytomous unconditional logistic regression models, respectively. Risk of NHL subtype was estimated for follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), T-cell lymphomas and other lymphomas; risk estimates are presented only for the two most common subtypes, follicular lymphoma and DLBCL, due to sparse numbers for other subtypes. P-values for the differences in risk estimates between follicular lymphoma and DLBCL were derived from a Wald chi-square statistic (1 degree of freedom). We adjusted risk estimates for sex, age (<45, 45-64, 65 + years), race and SEER area. Additional adjustment by education, smoking status, history of farming and having a first-degree relative with a history of NHL or any lymphoproliferative malignancy did not materially alter (>10%) the parameter estimates, and those factors were excluded from the final models.


   Results
Top
 Abstract
 Introduction
 Materials and methods
 Results
Discussion
 Funding
 Supplementary material
 References
 
Among women, 509 (83%) NHL cases and 413 (81%) controls reported use of hair coloring products (OR = 1.2; 95% CI 0.9, 1.6) (Table I). We observed little to no variation in risk by ever use of permanent dyes (OR = 1.1), semi-permanent dyes (OR = 1.1), temporary hair coloring (OR = 1.2) or progressive or other products (OR = 1.0). Women with 100 or more lifetime applications had a significantly elevated OR of 1.4 (95% CI 1.0, 2.0), but risk did not vary meaningfully by age at first use, frequency of use or duration of use (data not shown). Among men, 113 (16%) cases and 101 (19%) controls reported use of any hair coloring product (OR = 0.9; 95% CI 0.6, 1.2). Detailed analyses by product type, color, frequency, duration and calendar year of use were based on small numbers of male users and did not show any significant patterns of excess risk (data not shown); therefore the remainder of this report will present data for women only.


View this table:
[in this window]
[in a new window]

  		Table I. Number of non-Hodgkin lymphoma cases and controls and ORs according to hair coloring product use and sexa

 
Table II presents data by calendar year women began use of any hair coloring product and use of permanent dark color or intense tone products. Compared with women who never used hair coloring products, risk estimates were higher among women who began using hair dyes before 1980 than among women who began use in 1980 or later, particularly for permanent, intense tone (i.e. black, dark brown and dark blonde) products (before 1980—OR = 1.6; 95% CI 0.9, 2.7; 1980 or later—OR = 0.6; 95% CI 0.4, 1.1). Risk of NHL was 4-fold for women who used permanent, intense color tone products for ≥15 years prior to 1980 (17 cases, 4 controls, OR = 3.9; 95% CI 1.2, 12.5), but no consistent dose–response patterns were observed with frequency, duration or total lifetime applications (Table III). Analyses by NHL subtype revealed consistently higher risk estimates for follicular lymphoma than for DLBCL (Table IV).


View this table:
[in this window]
[in a new window]

  		Table II. Number of NHL cases and controls and ORs according to hair coloring product type, color, tone and calendar year of first use (women only)

 


View this table:
[in this window]
[in a new window]

  		Table III. Number of NHL cases and controls and ORs according to permanent hair coloring use before 1980, by color, tone, frequency, duration and total lifetime applications (women only)

 


View this table:
[in this window]
[in a new window]

  		Table IV. Number of follicular lymphoma and DLBCL NHL cases and controls and ORs according to hair coloring product use before 1980, by type, color and tone (women only)

 
Tables V and VI present data according to NAT2 phenotype and NAT1 genotype, respectively, and characteristics of permanent hair coloring use before 1980. Increased NHL risk estimates associated with hair dye use before 1980 were observed among NAT2 rapid/intermediate acetylators, but not among NAT2 slow acetylators (Table V). These findings were again most pronounced for use of permanent, intense tone products (NAT2 rapid/intermediate acetylators—OR = 3.3; 95% CI 1.3, 8.6; NAT2 slow acetylators—OR = 1.5; 95% CI 0.6, 3.6). Women with one or two copies of the NAT1*10 allele also had larger increases in NHL risk associated with use of permanent, dark color or permanent, intense tone products prior to 1980 than women with no copies of the NAT1*10 allele (Table VI). However, risks did not increase consistently with number of applications per year, years of use or total lifetime applications. Analyses by NHL subtype again revealed that the increased risk estimates for permanent hair coloring use before 1980 among women with the rapid/intermediate NAT2 phenotype, but not among slow NAT2 acetylators, and among women with one or two copies of the NAT1*10 allele, but not among women with no copies of the NAT1*10 allele, were more pronounced for follicular lymphoma than for DLBCL, albeit with wide CIs due to small numbers (data not shown).


View this table:
[in this window]
[in a new window]

  		Table V. Number of NHL cases and controls and ORs according to NAT2 phenotype and permanent hair coloring product use before 1980, by color, tone, frequency, duration and total lifetime applications (women only)

 


View this table:
[in this window]
[in a new window]

  		Table VI. Number of NHL cases and controls and ORs according to NAT1 genotype and permanent hair coloring use before 1980, by color, tone, frequency, duration and total lifetime applications (women only)

 
The NAT2 rapid/intermediate phenotype or the NAT1*10 allele alone did not increase risk of NHL among women who never used any hair coloring products (Supplementary Table I, available at Carcinogenesis Online). Risk was slightly elevated for women who began use of permanent hair dyes before 1980 among NAT2 slow acetylators and women without any copies of the NAT1*10 allele, and risk increased further among NAT2 rapid/intermediate acetylators or who had at least one copy of the NAT1*10 allele.


   Discussion
Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
Funding
 Supplementary material
 References
 
The etiology of NHL remains largely unknown apart from some rare genetic syndromes, acquired immunodeficiency syndrome associated with human immunodeficiency virus infection and a few other infections or medical conditions marked by immune dysregulation. Given the high prevalence of hair coloring products use, the presence of compounds in hair dyes that are carcinogenic and mutagenic in bioassays, and associations observed in previous epidemiologic studies, we evaluated the role of hair coloring products in this large case–control study by ascertaining detailed use data from interviews and jointly evaluating the exposure and potential genetic susceptibility.

On the whole, there was little evidence of increased risk of NHL among most users of hair dyes, but women who used dark color or intense tone (i.e. black, dark brown, dark blonde) permanent dyes prior to1980 had significantly increased risk. However, risk did not increase consistently with frequency, duration or total lifetime applications. These findings are consistent with several earlier studies (1,2,4–6,8), including the studies by Zhang et al. (5) and de Sanjose et al. (8) that also reported risk among long-term users of dark permanent hair coloring products who began use prior to 1980, but not among women who began use in recent decades after formulation changes were made [(10); J.Skare, 2004, personal communication]. We also observed that the risk estimates associated with use of dark color or intense tone permanent dyes prior to 1980 appeared to be higher for follicular lymphoma than for DLBCL, which is also consistent with the findings from Zhang et al. (5) and de Sanjose et al. (8), but should be confirmed in future research. Previous studies that have not shown associations between hair dye use and NHL (13–16) include the Nurses Health Study (13), which may be limited by ascertainment of exposure earlier in life than in case–control studies of NHL and by number of cases (21), and three case–control studies (14–16), two of which had no information on duration, age or (for one study only) shade. These detailed characteristics of use were important determinants of risk in the current study and others (32).

Our study showed significantly increased risks associated with use of dark color or intense tone permanent hair dyes before 1980 among women if they had the NAT2 rapid/intermediate phenotype or if they had one or two copies of the NAT1*10 allele, but not if they were slow NAT2 acetylators or had no copies of the NAT1*10 allele. In an earlier report from this study (24), we observed increased risk for NHL among individuals with the NAT1*10/10 genotype compared with individuals with other NAT1 genotypes, and a dose-dependent increase in risk among NAT2 intermediate and rapid acetylators in comparison with slow acetylators. These patterns were less evident among women than men, but not significantly so, accounting for the null association between NAT1 and NAT2 genetic variation and NHL risk presented here. The first study to examine malignant lymphoma in relation to acetylator status, using dapsone to determine acetylator phenotype, failed to find an association, possibly due to chance in this small study (33). Four previous epidemiologic studies, which had smaller numbers of subjects and genotyped fewer functional or potentially functional SNPs compared with our study, also observed no association between NAT1 or NAT2 genotypes and NHL risk (34–36), although one study suggested an association between the NAT2 slow-acetylation phenotype and low-grade lymphoma (37). There are no previous studies of NAT1 and NAT2 in relation to hair dye use and NHL risk. One study of bladder cancer has shown increased risk for hair dyes among NAT2 slow acetylators and those lacking the NAT1*10 allele (38–40), whereas another study showed no association between hair dyes and risk of bladder cancer, even after stratifying by NAT1 and NAT2 (41). The distribution and levels of NAT expression is tissue specific, however, with NAT1 present in most tissues and NAT2 expressed predominantly in the liver and gastrointestinal tracts (42). Hair dyes are most likely to first encounter NAT1 in the skin, where it may affect metabolism of aromatic amines (42,43). The phenotype of NAT1*10 is unclear, although the NAT1*10 has been shown in some studies to be the rapid allele (42–44). NAT1 and NAT2 both detoxify and activate various aromatic amines. Increased risk of NHL associated with hair coloring product use among NAT2 rapid/intermediate acetylators is consistent with activation of aryldiamines via N-acetylation (31,45).

The exact compounds in hair dyes that could increase risk of lymphoma are not known because publicly available information on hair dye formulations and contents and changes over time is limited. Some hair dye compounds that were typically used in dark, permanent dyes and have been found to be carcinogenic or mutagenic in animal studies, such as 2,4-diaminoanisole (also called 4-methoxy-m-phenylenediamine or 4MMPD), 2,4-diaminotoluene and 4-amino-2-nitrophenol, were removed by the manufacturers in the late 1970s and early 1980s, although others, such as 2-nitro-p-phenylenediamine, were still in use in the late 1990s (10,19). Current hair dye formulations have also been shown to contain 4-aminobiphenyl, which is known to be a bladder carcinogen but has not been linked to lymphoma risk (46). In the late 1970s and early 1980s, manufacturers also removed some carcinogenic azo dyes, such as Direct Black 38 and Direct Blue 6 (10,19,47), which are metabolized to benzidine, a known bladder carcinogen that has been associated with risk of lymphoma in some studies (48,49). Importantly, N-acetylation activates benzidine from benzidine-based dye exposure in vivo in humans to form highly reactive DNA-binding compounds, which can gain access to the hematopoietic compartment (50). Other undocumented changes in hair dye formulations and contents are also likely to have occurred. Based on the limited availability of information on hair dye contents, our observations of increased NHL risk among women who used dark color or intense tone permanent hair dyes before 1980 are consistent with known changes in hair dye formulations.

The strengths of this study include its population-based design, relatively large number of cases, detailed exposure data, calendar time of the exposure histories and incorporation of genetic susceptibility. Our study was based on over 1300 NHL cases (over 600 women), was able to evaluate the effect of the product changes over time and collected detailed hair coloring product histories based on methods developed by Johns Hopkins University and Clairol (51). Our study was the first NHL investigation to consider hair dye tone, an important determinant of risk, instead of color alone, and acetylation status. Our study was also the first to compute the actual frequency, duration and cumulative use of hair coloring products prior to 1980, rather than just stratifying by first use prior to 1980 versus 1980 or after, as has been done previously. If the calendar period of use does, in fact, affect NHL risk associated with hair coloring product use, this method of exposure assessment should substantially reduce exposure misclassification. Despite our more detailed assessment, we still did not observe consistent patterns in risk with frequency, duration or total lifetime applications. Potential confounders were dealt with by exclusion (HIV-positive subjects), adjusted for in the analysis (age, sex, study area) or found not to meaningfully affect risk estimates (education, smoking status, history of farming and having a first-degree relative with a history of NHL or any lymphoproliferative malignancy).

Although our finding that the increased NHL risk was limited to women who used dark color or intense tone permanent hair dyes before 1980 is consistent with the other studies that also considered time period of use (5,8), we cannot rule out the possibility that we observed no increased risk with hair dye use after 1980 because insufficient time has passed for the induction/latency period. Additional potential limitations of the current study include the low response rates, possible misclassification or bias in exposure data, possible confounding, disease heterogeneity within NHL and chance. The loss of eligible subjects due to refusal to participate is typical of current population-based studies (52), and we know of no data suggesting differential participation by hair dye use. In our study, demographic characteristics (age, education, sex) for individuals who provided blood compared with those who provided buccal cells and compared with those who provided neither blood nor buccal cell samples were equivalent within each study site (53). Errors in recall of hair coloring product use are likely to be small for ever versus never use, color and tone, but may be greater for reporting age started and stopped, and frequency of use. Although our results by NHL subtype were consistent with previous literature, confirmation of differences in the effects of hair dye use by NHL subtype is warranted. Finally, chance may have played a role in our findings, particularly given the large number of comparisons made, although our findings showed internal consistency.

In summary, NHL risk was elevated among women who used dark color or intense tone permanent hair dyes before 1980, particularly for those women with the rapid/intermediate NAT2 phenotype and those women with one or two copies of the NAT1*10 allele. There was no evidence of increased risk of NHL among women who began hair dye use after 1980, nor among men.


   Funding
Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 Funding
Supplementary material
 References
 
National Cancer Institute (contracts N01-PC-67010, N01-PC-67008, N01-PC-67009, N01-PC-65064 and N02-PC-71105)/National Institutes of Health Intramural Research Program. Studies at the University of Louisville were supported by National Cancer Institute (grant CA-34627).


   Supplementary material
Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 Funding
 Supplementary material
References
 
Supplementary Table 1 can be found at http://carcin.oxfordjournals.org/.


   Acknowledgments
 
The authors gratefully acknowledge the contributions of Ronald K. Ross, MD, University of Southern California, who participated in the early stages of this project before his untimely death. We also thank Michael Stagner of Information Management Services, Incorporated, for providing programming support; Geoffrey Tobias, National Cancer Institute, for study administration; Westat, Incorporated, for serving as the coordinating center; SeraCare BioServices for specimen handling; the NCI Core Genotyping Facility and the SEER study coordinators, interviewers and support staff for their diligent work.

Author contributions: Dr L.M.M. had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Dr L.M.M. also conducted the statistical analysis, and Drs L.M.M. and S.H.Z. drafted the manuscript. All authors contributed to the study conception and design, acquisition of data, interpretation of data and critical revision of the manuscript for important intellectual content.

Conflict of interest: Dr D.W.H. is a consultant for hair dye manufacturers. All other authors declare no conflict of interest.


   References
Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 Funding
 Supplementary material
 References
 

  1. Cantor KP, et al. Hair dye use and risk of leukemia and lymphoma. Am. J. Public Health (1988) 78:570–571.[Abstract/Free Full Text]
  2. Zahm SH, et al. Use of hair coloring products and the risk of lymphoma, multiple myeloma, and chronic lymphocytic leukemia. Am. J. Public Health (1992) 82:990–997.[Abstract/Free Full Text]
  3. Thun MJ, et al. Hair dye use and risk of fatal cancers in U.S. women. J. Natl Cancer Inst. (1994) 86:210–215.[Abstract/Free Full Text]
  4. Altekruse S, et al. Deaths from hematopoietic and other cancers in relation to permanent hair dye use in a large prospective study (United States). Cancer Causes Control (1999) 10:617–625.[CrossRef][ISI][Medline]
  5. Zhang Y, et al. Hair-coloring product use and risk of non-Hodgkin's lymphoma: a population-based case-control study in Connecticut. Am. J. Epidemiol. (2004) 159:148–154.[Abstract/Free Full Text]
  6. Benavente Y, et al. Regular use of hair dyes and risk of lymphoma in Spain. Int. J. Epidemiol. (2005) 34:1118–1122.[Abstract/Free Full Text]
  7. Takkouche B, et al. Personal use of hair dyes and risk of cancer: a meta-analysis. JAMA (2005) 293:2516–2525.[Abstract/Free Full Text]
  8. de Sanjose S, et al. Association between personal use of hair dyes and lymphoid neoplasms in Europe. Am. J. Epidemiol. (2006) 164:47–55.[Abstract/Free Full Text]
  9. Rollison DE, et al. Personal hair dye use and cancer: a systematic literature review and evaluation of exposure assessment in studies published since 1992. J. Toxicol. Environ. Health B Crit Rev. (2006) 9:413–439.[CrossRef][Medline]
  10. Corbett J. An historical review of the use of dye precursors in the formulation of commercial oxidation hair dyes. Dyes Pigments (1999) 41:127–136.[CrossRef]
  11. Ames BN, et al. Hair dyes are mutagenic: identification of a variety of mutagenic ingredients. Proc. Natl Acad. Sci. USA (1975) 72:2423–2427.[Abstract/Free Full Text]
  12. Sontag JM. Carcinogenicity of substituted-benzenediamines (phenylenediamines) in rats and mice. J. Natl Cancer Inst. (1981) 66:591–602.[ISI][Medline]
  13. Grodstein F, et al. A prospective study of permanent hair dye use and hematopoietic cancer. J. Natl Cancer Inst. (1994) 86:1466–1470.[Abstract/Free Full Text]
  14. Holly EA, et al. Hair-color products and risk for non-Hodgkin's lymphoma: a population-based study in the San Francisco bay area. Am. J. Public Health (1998) 88:1767–1773.[Abstract/Free Full Text]
  15. Miligi L, et al. Occupational, environmental, and life-style factors associated with the risk of hematolymphopoietic malignancies in women. Am. J. Ind. Med. (1999) 36:60–69.[CrossRef][ISI][Medline]
  16. Tavani A, et al. Hair dye use and risk of lymphoid neoplasms and soft tissue sarcomas. Int. J. Cancer (2005) 113:629–631.[CrossRef][ISI][Medline]
  17. IARC. Monographs on the Evaluation of Carcinogenic Risks to Humans: Occupational Exposures of Hairdressers and Barbers and Personal Use of Hair Colourants; Some Hair Dyes, Cosmetic Colourants, Industrial Dyestuffs, and Aromatic Amines. (1993) 57. Lyon, France: IARC. 7–398.
  18. Hein DW. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat. Res. (2002) 506–507:65–77.
  19. Hecht A. (1978) Hair Dyes: A Look at Safety and Regulation. 311–254/53. HEW Publication No. (FDA) 78-5010. U.S. Government Printing Office, Rockville, MD.
  20. Kline and Company Incorporated. Salon Hair Care USA 2003 (2004) Little Falls, NJ: Kline and Company, Inc.
  21. Zahm SH, et al. Hair coloring products: safe or still suspect? J. Natl Cancer Inst. (1994) 86:941–944.[Free Full Text]
  22. Cerhan JR, et al. Anthropometrics, physical activity, related medical conditions, and the risk of non-Hodgkin lymphoma. Cancer Causes Control (2005) 16:1203–1214.[CrossRef][ISI][Medline]
  23. Colt JS, et al. Residential insecticide use and risk of non-Hodgkin's lymphoma. Cancer Epidemiol. Biomarkers Prev. (2006) 15:251–257.[Abstract/Free Full Text]
  24. Morton LM, et al. Genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2) and risk of non-Hodgkin lymphoma. Pharmacogenet. Genomics (2006) 16:537–545.[ISI][Medline]
  25. Percy C, Van Holten V, Muir C, eds. International Classification of Diseases for Oncology (1990) 2nd edn. Geneva: World Health Organization.
  26. Casady R, et al. Stratified telephone survey designs. Surv. Methodol. (1993) 19:103–113.
  27. Garcia-Closas M, et al. Collection of genomic DNA from adults in epidemiological studies by buccal cytobrush and mouthwash. Cancer Epidemiol. Biomarkers Prev. (2001) 10:687–696.[Abstract/Free Full Text]
  28. Packer BR, et al. SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucleic Acids Res. (2006) 34(suppl. 1):D617–D621.[Abstract/Free Full Text]
  29. Hein DW, et al. Update on consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenetics (2000) 10:291–292.[CrossRef][ISI][Medline]
  30. Hein DW, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol. Biomarkers Prev. (2000) 9:29–42.[Abstract/Free Full Text]
  31. Hein DW. N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene (2006) 25:1649–1658.[CrossRef][ISI][Medline]
  32. Zahm SH, et al. Hair dye use and non-Hodgkin lymphoma. JAMA (2005) 294:1205.[Free Full Text]
  33. Philip P, et al. Acetylation and oxidation phenotypes in malignant lymphoma. Cancer Chemother. Pharmacol. (1987) 20:235–238.[CrossRef][ISI][Medline]
  34. Chiu BCH, et al. Association of NAT and GST polymorphisms with non-Hodgkin's lymphoma: a population-based case-control study. Br. J. Haematol. (2005) 128:610–615.[CrossRef][ISI][Medline]
  35. Kerridge I, et al. Association between xenobiotic gene polymorphisms and non-Hodgkin's lymphoma risk. Br. J. Haematol. (2002) 118:477–481.[CrossRef][ISI][Medline]
  36. Lemos MC, et al. Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias. Carcinogenesis (1999) 20:1225–1229.[Abstract/Free Full Text]
  37. William BM, et al. Acetylator phenotyping in patients with malignant lymphomas, using caffeine as the metabolic probe. Pol. J. Pharmacol. (2004) 56:445–449.[ISI][Medline]
  38. Gago-Dominguez M, et al. Use of permanent hair dyes and bladder cancer risk. Int. J. Cancer (2001) 91:575–579.[CrossRef][ISI][Medline]
  39. Gago-Dominguez M, et al. Permanent hair dyes and bladder cancer: risk modification by cytochrome P4501A2 and N-acetyltransferases 1 and 2. Carcinogenesis (2003) 24:483–489.[Abstract/Free Full Text]
  40. Gago-Dominguez M, et al. Use of permanent hair dyes and bladder cancer risk. Int. J. Cancer (2001) 94:905–906.[CrossRef][ISI]
  41. Kogevinas M, et al. Hair dye use is not associated with risk for bladder cancer: evidence from a case-control study in Spain. Eur. J. Cancer (2006) 42:1448–1454.[CrossRef][ISI][Medline]
  42. Pompeo F, et al. The pharmacogenetics of NAT: structural aspects. Pharmacogenomics (2002) 3:19–30.[CrossRef][ISI][Medline]
  43. Rodrigues-Lima F, et al. Regulation of the activity of the human drug metabolizing enzyme arylamine N-acetyltransferase 1: role of genetic and non-genetic factors. Curr. Pharm. Des. (2004) 10:2519–2524.[CrossRef][ISI][Medline]
  44. Hein DW, et al. Pharmacogenetics of the arylamine N-acetyltransferases: a symposium in honor of Wendell W. Weber. Drug Metab. Disp. (2000) 28:1425–1432.[ISI][Medline]
  45. Carreon T, et al. NAT2 slow acetylation and bladder cancer in workers exposed to benzidine. Int. J. Cancer (2006) 118:161–168.[CrossRef][ISI][Medline]
  46. Turesky RJ, et al. Identification of aminobiphenyl derivatives in commercial hair dyes. Chem. Res. Toxicol. (2003) 16:1162–1173.[CrossRef][ISI][Medline]
  47. Van Duuren BL. Carcinogenicity of hair dye components. J. Environ. Pathol. Toxicol. (1980) 3:237–251.[ISI][Medline]
  48. Chen JG. A cohort study on the cancer experience among workers exposed to benzidine-derived dyes in Shanghai leather-tanning industry. Zhonghua Yu Fang Yi Xue Za Zhi (1990) 24:328–331.[Medline]
  49. Mao Y, et al. Canadian Cancer Registries Epidemiology Research Group. Non-Hodgkin's lymphoma and occupational exposure to chemicals in Canada. Ann. Oncol. (2000) 11(suppl. 1):S69–S73.
  50. Beyerbach A, et al. Hemoglobin adducts in workers exposed to benzidine and azo dyes. Carcinogenesis (2006) 27:1600–1606.[Abstract/Free Full Text]
  51. Correa A, et al. Final Report to Clairol, Inc.—Hair Dye Use Questionnaires: Development and Reliability Assessment (1996) Baltimore, MD: The Johns Hopkins University School of Hygiene and Public Health.
  52. Morton LM, et al. Reporting participation in epidemiologic studies: a survey of practice. Am. J. Epidemiol. (2006) 163:197–203.[Abstract/Free Full Text]
  53. Bhatti P, et al. Genetic variation and willingness to participate in epidemiologic research: data from three studies. Cancer Epidemiol. Biomarkers Prev. (2005) 14:2449–2453.[Abstract/Free Full Text]
Received March 13, 2007; revised May 11, 2007; accepted May 12, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CarcinogenesisHome page
J. E. Bailey and J. A. Skare
Reply: Letter to the editor in response to Morton et al. (2007) Carcinogenesis, 28, 1759-1764
Carcinogenesis, September 1, 2008; 29(9): 1851 - 1851.
[Full Text] [PDF]

Home page
 Am J EpidemiolHome page
Y. Zhang, S. D. Sanjose, P. M. Bracci, L. M. Morton, R. Wang, P. Brennan, P. Hartge, P. Boffetta, N. Becker, M. Maynadie, et al.
Personal Use of Hair Dye and the Risk of Certain Subtypes of Non-Hodgkin Lymphoma
Am. J. Epidemiol., June 1, 2008; 167(11): 1321 - 1331.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
S. H. Zahm, L. M. Morton, L. Bernstein, S. S. Wang, J. S. Colt, R. K. Severson, R. Welch, and P. Hartge
Re: Hair dye use, genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma, author response
Carcinogenesis, May 1, 2008; 29(5): 1084 - 1085.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary Data
Right arrow All Versions of this Article:
28/8/1759    most recent
bgm121v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Morton, L. M.
Right arrow Articles by Zahm, S. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morton, L. M.
Right arrow Articles by Zahm, S. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?